Lifecore (LFCR) Biomedical announced that it has signed a new 10-year commercial manufacturing and supply agreement with a key existing customer. This represents the latest agreement signed between the two companies to support the advancement of a novel ophthalmic therapeutic through clinical development and onto the market. In conjunction with the commercial manufacturing and supply agreement, Lifecore has also signed a multi-million-dollar statement of work detailing a range of fill and finish CDMO services that will further advance this program towards potential regulatory approval and commercialization. Under the terms of this new statement of work, Lifecore will be responsible for manufacturing a variety of batches of the drug candidate, including multiple Process Performance Qualification batches.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFCR:
- Lifecore receives accelerated payment of $10M in proceeds from equipment sale
- Lifecore names Mark DaFonseca as Chief Commercial Officer
- UnitedHealth downgraded, Home Depot upgraded: Wall Street’s top analyst calls
- Lifecore initiated with an Outperform at William Blair
- Lifecore Biomedical’s Promising Growth Trajectory: Buy Rating with 34% Upside Potential